SELLAS Life Sciences Group (NASDAQ:SLS) Shares Gap Down – Time to Sell?

Shares of SELLAS Life Sciences Group, Inc. (NASDAQ:SLS – Get Free Report) gapped down before the market opened on Thursday. The stock had previously closed at $17.95, but opened at $15.38. SELLAS Life Sciences Group shares last traded at $15.7370, with a volume of 15,143,438 shares changing hands.

Recent SELLAS Life Sciences Group Headlines

These are some of the SLS headlines that stood out recently:

  • Positive Sentiment: SELLAS reported positive Phase 3 REGAL trial data for galinpepimut-S in acute myeloid leukemia, a potential clinical catalyst for its cancer-treatment pipeline. Article: Positive Phase 3 REGAL trial data
  • Positive Sentiment: The $150 million offering will provide capital to support development of the company’s oncology candidates, including GPS and SLS009. Article: SELLAS prices $150 million offering
  • Negative Sentiment: SELLAS priced 11.54 million new shares at $13 each, with an underwriter option for up to 1.73 million additional shares. The added supply and discounted price raise dilution concerns and are the immediate reported catalyst for the stock’s decline; the offering is expected to close November 20. Article: Shares sink after offering pricing

Analysts Set New Price Targets

A number of equities analysts have recently commented on SLS shares. Alliance Global Partners restated a “buy” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, August 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Thursday, October 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $10.00.

View Our Latest Research Report on SELLAS Life Sciences Group

SELLAS Life Sciences Group Trading Down 18.3%

The stock has a market cap of $2.99 billion, a PE ratio of -72.52 and a beta of 2.73. The company’s 50 day moving average is $11.09 and its 200-day moving average is $8.94.

SELLAS Life Sciences Group (NASDAQ:SLS – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05).

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC grew its position in shares of SELLAS Life Sciences Group by 293.2% during the third quarter. GAMMA Investing LLC now owns 2,186 shares of the company’s stock worth $27,000 after buying an additional 1,630 shares in the last quarter. California State Teachers Retirement System raised its holdings in SELLAS Life Sciences Group by 22.4% in the first quarter. California State Teachers Retirement System now owns 9,337 shares of the company’s stock valued at $39,000 after acquiring an additional 1,709 shares in the last quarter. Nykredit A S acquired a new stake in SELLAS Life Sciences Group in the second quarter valued at $27,000. Robinhood Markets Inc. acquired a new stake in SELLAS Life Sciences Group in the third quarter valued at $33,000. Finally, Pictet Asset Management Holding SA raised its holdings in SELLAS Life Sciences Group by 15.4% in the third quarter. Pictet Asset Management Holding SA now owns 27,688 shares of the company’s stock valued at $341,000 after acquiring an additional 3,704 shares in the last quarter. Hedge funds and other institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Company Profile

(Get Free Report)

SELLAS Life Sciences Group is a clinical-stage biopharmaceutical company focused on developing treatments for cancer. Its research centers on immunotherapies and other therapies intended to address hematologic malignancies and solid tumors. The company does not have an established portfolio of marketed products; its work is focused on clinical development. Its pipeline includes galinpepimut-S (GPS), an immunotherapy designed to target the Wilms’ tumor 1 (WT1) protein, which is found in several types of cancer.

Further Reading

Receive News & Ratings for SELLAS Life Sciences Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SELLAS Life Sciences Group and related companies with MarketBeat.com's FREE daily email newsletter.